JP2024547001A - 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法 - Google Patents

抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法 Download PDF

Info

Publication number
JP2024547001A
JP2024547001A JP2024536189A JP2024536189A JP2024547001A JP 2024547001 A JP2024547001 A JP 2024547001A JP 2024536189 A JP2024536189 A JP 2024536189A JP 2024536189 A JP2024536189 A JP 2024536189A JP 2024547001 A JP2024547001 A JP 2024547001A
Authority
JP
Japan
Prior art keywords
fragment
antibody
protofibril
tau
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024536189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024547001A5 (https=
Inventor
ラリサ レイダーマン，
ジン ジョウ，
リン クレイマー，
マイケル イリザリー，
パラヴィ サチデブ，
ショバ ダッダ，
デイビッド リ，
クリスティン ワイルドスミス，
バルド， ポー アセベス
スミット ラワル，
彰比古 小山
チャド スワンソン，
道雄 兼清
ジューン カプロウ，
デイビッド バーベル，
イシャニ ランドリー，
誠一 早戸
ロバート ゴードン，
ランドール ベイトマン，
エリック マクデイド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2021/000937 external-priority patent/WO2023111618A1/en
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of JP2024547001A publication Critical patent/JP2024547001A/ja
Publication of JP2024547001A5 publication Critical patent/JP2024547001A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nuclear Medicine (AREA)
JP2024536189A 2021-12-17 2022-11-08 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法 Pending JP2024547001A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163291315P 2021-12-17 2021-12-17
US63/291,315 2021-12-17
IBPCT/IB2021/000937 2021-12-17
PCT/IB2021/000937 WO2023111618A1 (en) 2021-12-17 2021-12-17 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
PCT/US2022/079509 WO2023114586A1 (en) 2021-12-17 2022-11-08 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody

Publications (2)

Publication Number Publication Date
JP2024547001A true JP2024547001A (ja) 2024-12-26
JP2024547001A5 JP2024547001A5 (https=) 2025-12-19

Family

ID=84387973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024536189A Pending JP2024547001A (ja) 2021-12-17 2022-11-08 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法

Country Status (8)

Country Link
US (1) US20250051427A1 (https=)
EP (1) EP4448005A1 (https=)
JP (1) JP2024547001A (https=)
KR (1) KR20240115910A (https=)
AU (1) AU2022410770A1 (https=)
CA (1) CA3242280A1 (https=)
MX (1) MX2024007288A (https=)
WO (1) WO2023114586A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025019457A1 (en) 2023-07-15 2025-01-23 Eisai R&D Management Co., Ltd. Antimicrobial peptides
WO2025049938A1 (en) * 2023-08-31 2025-03-06 Florida Atlantic University Board Of Trustees Non-invasive delivery method of antibodies to the brain for treatment of brain diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
US20210324056A1 (en) * 2018-07-24 2021-10-21 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
CN112187401B (zh) 2019-07-03 2022-06-14 华为技术有限公司 多时间单元传输方法及相关装置
US11877315B2 (en) 2020-09-15 2024-01-16 Qualcomm Incorporated Wireless device digital beamforming capability indication

Also Published As

Publication number Publication date
KR20240115910A (ko) 2024-07-26
EP4448005A1 (en) 2024-10-23
WO2023114586A1 (en) 2023-06-22
MX2024007288A (es) 2024-06-28
AU2022410770A1 (en) 2024-06-13
CA3242280A1 (en) 2023-06-22
US20250051427A1 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
CA3158513A1 (en) Methods for treating alzheimer's disease
JP2024547001A (ja) 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法
WO2023111618A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
TW202334201A (zh) 抗Ｔａｕ抗體之組成物、劑型及方法
TWI894689B (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
US20220127346A1 (en) Methods of Safe Administration of Anti-Tau Antibody
KR20240053620A (ko) 항-a베타 프로토피브릴 항체의 피하 제형 및 이를 사용하는 방법
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку
CN118450905A (zh) 使用抗淀粉样蛋白β初原纤维抗体和抗τ蛋白抗体的方法
US20250361292A1 (en) Methods of delaying or preventing the onset of alzheimer's disease using crenezumab
TW202513583A (zh) 使用抗Ａβ初原纖維抗體之治療方法
WO2025240435A1 (en) Methods of treating neurological disorders with anti-abeta antibodies
TW202541846A (zh) 以抗類澱粉蛋白β (ABETA)抗體治療神經病症之方法
EA051320B1 (ru) Способ безопасного введения антитела к тау-белку

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20240911

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20240911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209